Bifogade filer
Interim Report Q1 2021
Kurs
-1,49%
Prenumeration
Kalender
| Est. tid* | ||
| 2025-10-21 | 08:20 | Kvartalsrapport 2025-Q3 |
| 2025-08-27 | 08:20 | Kvartalsrapport 2025-Q2 |
| 2025-05-16 | - | X-dag ordinarie utdelning NANEXA 0.00 SEK |
| 2025-05-15 | - | Årsstämma |
| 2025-05-06 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-19 | - | Bokslutskommuniké 2024 |
| 2025-02-13 | - | Extra Bolagsstämma 2024 |
| 2024-11-07 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-27 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-16 | - | X-dag ordinarie utdelning NANEXA 0.00 SEK |
| 2024-05-15 | - | Årsstämma |
| 2024-05-03 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-21 | - | Bokslutskommuniké 2023 |
| 2023-11-20 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-23 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-09 | - | Årsstämma |
| 2023-05-30 | - | X-dag ordinarie utdelning NANEXA 0.00 SEK |
| 2023-05-04 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-10-25 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-26 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-10 | - | X-dag ordinarie utdelning NANEXA 0.00 SEK |
| 2022-06-09 | - | Årsstämma |
| 2022-04-20 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-11-10 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-20 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-06 | - | Kvartalsrapport 2021-Q1 |
| 2021-05-03 | - | X-dag ordinarie utdelning NANEXA 0.00 SEK |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-11-12 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-03 | - | X-dag ordinarie utdelning NANEXA 0.00 SEK |
| 2020-06-02 | - | Årsstämma |
| 2020-05-15 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-12 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-06-12 | - | X-dag ordinarie utdelning NANEXA 0.00 SEK |
| 2019-06-11 | - | Årsstämma |
| 2019-05-15 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-20 | - | Bokslutskommuniké 2018 |
| 2018-11-12 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-22 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-30 | - | X-dag ordinarie utdelning NANEXA 0.00 SEK |
| 2018-05-29 | - | Årsstämma |
| 2018-05-15 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-20 | - | Bokslutskommuniké 2017 |
| 2017-11-10 | - | Kvartalsrapport 2017-Q3 |
| 2017-10-23 | - | Extra Bolagsstämma 2017 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-06-13 | - | X-dag ordinarie utdelning NANEXA 0.00 SEK |
| 2017-06-12 | - | Årsstämma |
| 2017-05-17 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-15 | - | Bokslutskommuniké 2016 |
| 2016-11-16 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-17 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-27 | - | X-dag ordinarie utdelning NANEXA 0.00 SEK |
| 2016-05-26 | - | Årsstämma |
| 2016-05-12 | - | Kvartalsrapport 2016-Q1 |
| 2016-04-06 | - | Extra Bolagsstämma 2016 |
| 2016-02-25 | - | Bokslutskommuniké 2015 |
| 2015-11-19 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-20 | - | Kvartalsrapport 2015-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
"The development of Nanexa is continuing and at the beginning of the quarter we started our second proprietary product project, NEX-20. The choice of multiple myeloma as our second indication fits well with myelodysplastic syndrome (MDS) in NEX-18 and creates an interesting portfolio in haematological cancer. In 2021, we intend to identify another project, NEX-21, where PharmaShell® can create another unique product with major potential." David Westberg, CEO Nanexa AB.
Significant events during the first quarter
- Applied Ventures invested USD 1 million in a directed share issue in accordance with the investment agreement entered into at the end of 2020, which provided the company with approximately SEK 8 million after issue costs.
- Nanexa decided that the company's second proprietary product project, NEX-20, will focus on developing a long-acting formulation of lenalidomide for the treatment of multiple myeloma.
- Nanexa signed an evaluation agreement with an unnamed European biotech company that has a development project in the cardiovascular area, where PharmaShell® can enable a long-acting injectable product.
- Redemption of warrants of series TO2 was carried out during the period 1-15 February 2021, with a subscription rate of 97.5%, which brought SEK 24.9 million to the company, before costs of issue. The number of shares and votes in the company thus increased by 2,956,588 to 24,866,934 shares and votes.
- Jonas Fransson was recruited as head of pharmaceutical development and will join Nanexa’s management team as of 1 May 2021.
Significant events after the end of the period
- Applied Ventures invested a further USD 0.5 million through the exercise of warrants issued in connection with the directed share issue in Q1 2021. Nanexa received SEK 4.3 million through the issue before issue costs and the number of shares and votes in the company thus increased by 480,879 to 25,347,813 shares and votes.
- Nanexa started its first clinical trial in April 2021. It is a phase I study in the NEX-18 project to study pharmacokinetics, safety and tolerability.
Summary of the reporting period 1 January - 31 March 2021
- Turnover amounted to: TSEK 536 (1,192)
- Operating profit (EBIT) amounted to: TSEK -6,623 (-3,469)
- Profit after tax amounted to: TSEK -6,670 (-3,525)
- Earnings per share amounted to: SEK -0.29 (-0.22)
- Cash flow for the period was: TSEK 22,158 (32,672)
- Cash and cash equivalents at end of period: TSEK 34,849 (44,050)
Figures in brackets refer to the corresponding period in the previous year.
For additional information, please contact:
David Westberg – CEO, Nanexa AB (publ)
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com
Erik Penser Bank is the company’s Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se
About Nanexa AB (publ)
Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, a new and groundbreaking drug delivery system with great potential for a number of medical substance types and indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with several pharma companies, among others AstraZeneca.
Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).